
Fierce Pharma Asia—Congress' US-China biotech report; NIH's database ban; GSK's ABL neuroscience deal
A special congressional committee has recommended a $15 billion investment to boost the United States' biotech advantage over China. The NIH has blocked access to some health and genomics databases for China and other countries. GSK signed a deal worth …